TriSol Medical News
2 articles
growth-positive
Trisol announces successful implants of its Transcatheter Tricuspid Valve in the US
Trisol Medical Ltd. has successfully conducted two implants of the Trisol Transcatheter Tricuspid Valve Replacement in the United States as part of an FDA approved Early Feasibility Study. The procedures were performed at the Piedmont Heart Institute in Atlanta, Georgia and the University of Virginia Health System in Charlottesville, VA. The patients, both women suffering from severe symptomatic tricuspid regurgitation, saw significant reductions in their TR levels and were discharged from the hospital within two days of the procedure. Trisol aims to complete its EFS and initiate pivotal studies in 2024.
CustomersPartners
growth-positive
Heart valve co Trisol Medical raises $2.7m
Israeli medical start-up Trisol Medical has raised $2.7m in a funding round featuring US, Israeli and Chinese investors. Trisol, which recently graduated from the Alon MedTech Ventures incubator, is developing a heart valve that can be implanted via catheterisation. The company is targeting the tricuspid valve, which it believes could provide a solution for millions of patients worldwide suffering from substantial leaking from the tricuspid valve who are unable to undergo open heart surgery. Trisol estimates the market for tricuspid valves implanted by catheterisation at $6 billion.
Investment
